Clinical trial
A Multicenter, Open-label Study to Assess the Efficacy and Safety of Infliximab (REMICADE�) Therapy in Patients With Plaque Psoriasis Who Had an Inadequate Response to Etanercept (ENBREL�)
NCT00527072 is registered in ClinicalTrials.gov with Centocor Ortho Biotech Services, L.L.C. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open-label Study to Assess the Efficacy and Safety of Infliximab (REMICADE�) Therapy in Patients With Plaque Psoriasis Who Had an Inadequate Response to Etanercept (ENBREL�)
- Lead sponsor
- Centocor Ortho Biotech Services, L.L.C.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 31, 2007
- Completion date
- October 31, 2009
- Enrollment
- 217 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.